RD
RedHill Biopharma Ltd.
RDHL · NASDAQ
$0.55 -2.69% (-$0.02)
1M -9.14%
Market Cap $1.73M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.74
34.6% upside
Current Price
$0.55
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RDHL is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/B 0.40x
P/S 0.18x
EV/EBITDA N/A
Growth
0 /100
Declining Rev. growth 83.34%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Net margin 97.52%
Op. margin 110.40%
FCF margin 85.98%
Quality
7 /100
Poor ROA 36.74%
Asset turnover 0.38x
ROIC 167.51%
Debt
46 /100
Moderate Current ratio 0.34x
Int. coverage -7.99x
Debt/Equity 0.25x
Stability
1 /100
Unstable Rev. volatility 67.13%
EPS volatility 126.53%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RDHL
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dror Ben-Asher
Employees
13
Headquarters
Tel Aviv
Upcoming events
18 MAR
Earnings
Upcoming earnings report